Market revenue in 2023 | USD 16.4 million |
Market revenue in 2030 | USD 30.2 million |
Growth rate | 9.2% (CAGR from 2023 to 2030) |
Largest segment | Episomal reprogramming |
Fastest growing segment | MRNA Reprogramming |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Sendai Virus-based Reprogramming, MRNA Reprogramming, Episomal Reprogramming |
Key market players worldwide | Thermo Fisher Scientific Inc, Merck KGaA, Bio-Techne Corp, ReproCELL, Lonza Group Ltd, FUJIFILM Holdings Corp, Astellas Pharma Inc, Allele Biotech, Alstem, STEMCELL Technologies |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell reprogramming market will help companies and investors design strategic landscapes.
Episomal reprogramming was the largest segment with a revenue share of 32.93% in 2023. Horizon Databook has segmented the India cell reprogramming market based on sendai virus-based reprogramming, mrna reprogramming, episomal reprogramming covering the revenue growth of each sub-segment from 2018 to 2030.
The market for cell reprogramming in India is witnessing rapid progress due to initiatives and research conducted by companies and institutions in the country. For instance, in August 2023, researchers from the Indian Institute of Technology Guwahati (IIT-G) and scientists from Christian Medical College (CMC), Vellore, collaborated to introduce a method for converting regular human skin cells into pluripotent stem cells.
Traditionally, stem cells are derived from embryos or specific adult body parts, posing ethical and practical challenges. In contrast, scientists are exploring innovative approaches to transform common cells, such as blood cells or skin, into pluripotent stem cells known as iPSCs.
iPSCs offer a key advantage in generating patient-specific cells, which can be utilized for transplantation to the injured or degenerated tissue sites, minimizing the risk of immune rejection. This breakthrough has significant implications for advancing personalized and targeted therapies in regenerative medicine.
Horizon Databook provides a detailed overview of country-level data and insights on the India cell reprogramming market , including forecasts for subscribers. This country databook contains high-level insights into India cell reprogramming market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account